Genzyme Corporation

Optein, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Mcw Research Foundation, Inc.

Steven R Ledbetter

Richard J Roman

Robert G Holgate

Celia Patricia Hart

Catriona L Buchanan

Alexander R Duncan

Donna K Finch

Ashwani K Khanna

Celia P Hart

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Antibodies to TGF-&#x3b2;

The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Antibodies to TGF-beta

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF&#x3b2;), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, so-called 'pan-specific' antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Antibodies to TGF&#x3b2;

The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-&#x3b2; such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-&#x3b2; antagonist, e.g., an anti-TGF-&#x3b2; antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-&#x3b2; antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.

Use of TGF-&#x3b2; antagonists to limit nephrotoxicity of immunosuppressive agents

Growing community of inventors

Westborough, MA, United States of America

Steven R Ledbetter